IQVIA (NYSE:IQV) Releases Earnings Results, Misses Expectations By $0.21 EPS

IQVIA (NYSE:IQV) announced its quarterly earnings results on Thursday. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21), Zacks reports. IQVIA had a net margin of 9.17% and a return on equity of 28.17%. IQVIA updated its FY 2025 guidance to 11.700-12.100 EPS.

IQVIA Stock Performance

Shares of NYSE:IQV traded down $2.81 on Friday, reaching $207.15. The company’s stock had a trading volume of 363,646 shares, compared to its average volume of 1,385,062. The stock’s 50-day moving average is $200.53 and its two-hundred day moving average is $219.80. IQVIA has a 52-week low of $187.62 and a 52-week high of $261.73. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The stock has a market capitalization of $37.60 billion, a P/E ratio of 27.19, a PEG ratio of 2.15 and a beta of 1.48.

Analyst Upgrades and Downgrades

IQV has been the subject of several analyst reports. Redburn Atlantic initiated coverage on IQVIA in a report on Monday, October 14th. They set a “buy” rating and a $276.00 price objective for the company. Morgan Stanley cut their target price on IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Royal Bank of Canada reissued an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a research report on Wednesday, December 11th. BTIG Research downgraded IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday. Finally, Stifel Nicolaus cut their price target on IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a research report on Friday. Five investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $252.39.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.